| Drug Name |
Fospropofol disodium |
| Drug ID |
BADD_D00972 |
| Description |
Fospropofol is a water soluble prodrug and is converted to propofol in the liver. Fospropofol is a short acting hypnotic/sedative/anesthetic agent. Unlike propofol, does not cause injection-site pain as it is unable to activate TRPA1. FDA approved in December 2008.
Fospropofol is a Schedule IV controlled substance in the United States under the Controlled Substances Act. |
| Indications and Usage |
For monitored anaesthesia care sedation in patients undergoing diagnostic procedures like bronchoscopy and colonscopy or minor surgical procedures like arthroscopy and bunionectomy. |
| Marketing Status |
approved; illicit; investigational |
| ATC Code |
Not Available |
| DrugBank ID |
DB06716
|
| KEGG ID |
D04257
|
| MeSH ID |
C472965
|
| PubChem ID |
3038497
|
| TTD Drug ID |
D02EZM
|
| NDC Product Code |
66064-1034 |
| UNII |
30868AY0IF
|
| Synonyms |
fospropofol | Aquavan | Lusedra | fospropofol disodium | methanol, (2,6-bis(1-methylethyl)phenoxy)-, dihydrogen phosphate, disodium salt | GPI 15715 | GPI15715 |
